Carotenoids: Potential allies of cardiovascular health?

Food and Nutrition Research

Volumn 59, Issue , 2015, Pages

  Gammone, Maria Alessandra ^a   Riccioni, Graziano ^a,b   D'Orazio, Nicolantonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Beta cryptoxanthin; Cardiovascular; Carotenoids; Fucoxanthin; Lutein; Lycopene; Lycopene astaxanthin; Zeaxanthin

Indexed keywords

ANTIOXIDANT; ASTAXANTHIN; BETA CAROTENE; BETA CRYPTOXANTHIN; CAROTENOID; FUCOXANTHIN; LOW DENSITY LIPOPROTEIN; LYCOPENE; NITRIC OXIDE; PROTECTIVE AGENT; XANTHOPHYLL; ZEAXANTHIN;

ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DIETARY INTAKE; HEALTH STATUS; HUMAN; LIPOPHILICITY; MEDITERRANEAN DIET; NONHUMAN; OXIDATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; THERAPY EFFECT;

EID: 84922495868     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v59.26762     Document Type: Article

References (128)

1. Fassett RG, Coombes JS. Astaxanthin: A potential therapeutic agent in cardiovascular disease. Mar Drugs 2011; 3: 447-65.
2. McNulty H, Jacob RF, Mason RP. Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am J Cardiol 2008; 101: 20-9D.
3. Jackson H, Braun CL, Ernst H. The chemistry of novel xanthophyll carotenoids. Am J Cardiol 2008; 101: 50-7D.
4. Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem 2007; 18: 567-79.
5. World Health Organization. Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. Diet, nutrition, and the prevention of chronic disease. WHO Library Cataloguing-in-Publication Data, WHO Technical Report Series, No. 916. Geneva: 2003.
6. Neaton J, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and difference by age for 316, 099 white man. Multiple risk factor intervention trial research group. Arch Intern Med 1992; 152: 56-64.
7. Riccioni G. Carotenoids and cardiovascular disease. Curr Atheroscler Rep 2009; 11: 434-9.
8. Riccioni G, D'Orazio N, Speranza L, Di Ilio E, Glade M, Bucciarelli V, et al. Carotenoids and asymptomatic carotid atherosclerosis. J Biol Regul Homeost Agents 2010; 24: 447-52.
9. Schweigert F. Metabolism of carotenoids in mammals. Basel, Switzerland: Birkhauser Verlag; 1998.
10. Jyonouchi H, Sun S, Tomita Y, Gross MD. Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J Nutr 1995; 125: 2483-92.
11. Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: Applications for human health and nutrition. Trends Biotechnol 2003; 21: 210-16.
12. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae. Mol Nutr Food Res 2011; 55: 150-65.
13. Ellingsen I, Seljeflot I, Arnesen H, Tonstad S. Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis 2009; 19: 8-14.
14. Carty JL, Bevan R, Waller H, Mistry N, Cooke M, Lunec J, et al. The effects of vitamin C supplementation on protein oxidation in healthy volunteers. Biochem Biophys Res Commun 2000; 273: 729-35.
15. Carpenter KL, Kirkpatrick PJ, Weissberg PL, Challis IR, Dennis IF, Freeman MA, et al. Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. Free Radic Res 2003; 37: 1235-44.
16. Helmersson J, Arnlov J, Larsson A, Basu S. Low dietary intake of beta-carotene, alpha-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. Br J Nutr 2009; 101: 1775-82.
17. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008; 101: 58-68.
18. Nakano M, Onodera A, Saito E, Tanabe M, Yajima K, Takahashi J, et al. Effect of astaxanthin in combination with alpha-tocopherol or ascorbic acid against oxidative damage in diabetic ODS rats. J Nutr Sci Vitaminol 2008; 54: 329-34.
19. Iwamoto T, Hosoda K, Hirano R, Kurata H, Matsumoto A, Miki W, et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 2000; 7: 216-22.
20. Fassett RG, Coombes JS. Astaxanthin in cardiovascular health and disease. Molecules 2012; 17: 2030-48.
21. Choi SK, Park YS, Choi DK, Chang HI. Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol 2008; 18: 1990-6.
22. Khan SK, Malinski T, Mason RP, Kubant R, Jacob RF, Fujioka K, et al. Novel astaxanthin prodrug CDX-085 attenuates thrombosis in mouse model. Thromb Res 2010; 126: 299-305.
23. Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010; 209: 520-3.
24. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr Metab 2010; 7: 18.
25. Monroy-Ruiz J, Sevilla MÁ, Carrón R, Montero MJ. Astaxanthin-enriched diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol Res 2011; 63: 44-50.
26. Preuss HG, Echard B, Yamashita E, Perricone NV. High dose astaxanthin lowers blood pressure and increases insulin sensitivity in rats: Are these effects interdependent? Int J Med Sci 2011; 8: 126-38.
27. Hussein G, Nakamura M, Zhao Q, Iguchi T. Anti-hypertensive and neuro-protective effects of astaxanthin in experimental animals. Biol Pharm Bull 2005; 28: 47-52.
28. Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Davis MD, et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no.36. JAMA Ophthalmol 2014; 132: 272-7.
29. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994; 330: 1029-35.
30. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: A postintervention follow-up. JAMA 2003; 290: 476-85.
31. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res 1994; 54: 2038-43s.
32. Mercadante AZ, Egeland ES. Carotenoids with a C40 skeleton. In: Britton G, Liaaen-Jensen S, Pfander H, eds. Carotenoids Handbook. Basel, Switzerland: Birkhauser; 2004, p. 563.
33. Hu T, Liu D, Chen Y, Wu J, Wang S. Antioxidant activity of sulfated polysaccharide fractions extracted from Undaria pinnitafida in vitro. Int. J. Biol. Macromol 2010; 46: 193-8.
34. Sangeetha RK, Bhaskar N, Divakar S, Baskaran V. Bioavailability and metabolism of fucoxanthin in rats: Structural characterization of metabolites by LC-MS (APCI). Mol Cell Biochem 2010; 333: 299-310.
35. Hashimoto T, Ozaki Y, Taminato M, Das SK, Mizuno M, Yoshimura K, et al. The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. Br J Nutr 2009; 102: 242-8.
36. Das SK, Hashimoto T, Kanazawa K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim Biophys Acta 2008; 1780: 743-9.
37. Asai A, Sugawara T, Ono H, Nagao A. Biotransformation of fucoxanthinol in amarouciaxanthin A in mice and Hep-G2 cells: Formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 2004; 32: 205-11.
38. Asai A, Yonekura L, Nagao A. Low bioavailability of dietary epoxy-xanthophylls in humans. Br J Nutr 2008; 100: 273-7.
39. Matsumoto M, Hosokawa M, Matsukawa N, Hagio M, Shinoki A, Nishimukai M. Suppressive effects of the marine carotenoids, fucoxanthin and fucoxanthinol on triglyceride absorption in lymph duct-cannulated rats. Eur J Nutr 2010; 49: 243-9.
40. Hashimoto T, Ozaki Y, Mizuno M, Yoshida M, Nishitani Y, Azuma T, et al. Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract. Br J Nutr 2012; 107: 1566-9.
41. Mordenti J. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 1028-40.
42. Maeda H, Hosokawa M, Sashima T, Miyashita K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 2007; 55: 7701-6.
43. Gammone MA, Gemello E, Riccioni G, D'Orazio N. Marine bioactives and potential applications in sport. Marine Drugs 2014; 12: 2357-82.
44. D'Orazio N, Gemello E, Gammone MA, DeGirolamo M, Ficoneri C, Riccioni G. Fucoxantin: A treasure from sea. Mar Drugs 2012; 10: 604-16.
45. D'Orazio N, Gammone MA, Gemello E, DeGirolamo M, Cusenza S, Riccioni G. Marine bioactives: Pharmacological properties and potential applications against inflammatory diseases. Mar Drugs 2012; 10: 812-33.
46. Labruna G, Pasanisi F, Fortunato G, Nardelli C, Finelli C, Farinaro E, et al. Sequence analysis of the UCP1 gene in a severe obese population from Southern Italy. J Obes 2011; 2011: 269043.
47. Okada T, Mizuno Y, Sibayama S, Hosokawa M, Miyashita K. Antiobesity effects of Undaria lipid capsules prepared with phospholipids. J Food Sci 2011; 76: H2-6.
48. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of Xanthigen in the weight management of obese premenopausal women with non-Alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 2010; 12: 72-81.
49. Heilbronn LK, Noakes M, Clifton MP. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Atheroscler Thromb Vasc Biol 2001; 21: 968-70.
50. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
51. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipokines in obesity-related diseases. Horm Res 2003; 60: 56-9.
52. Nozaki M, Fukuhara A, Segawa K, Okuno Y, Abe M, Hosogai N, et al. NO dysregulates adipocytokine expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2007; 364: 33-9.
53. Park HJ, Lee MK, Park YB, Shin YC, Choi MS. Beneficial effects of Undaria pinnatifida ethanol extract on diet-inducedinsulin resistance in C57BL/6J mice. Food Chem Toxicol 2010; 13: 357-63.
54. Ikeda K, Kitamura A, Machida H, Watanabe M, Negishi H, Hiraoka J, et al. Effect of Undaria pinnatifida on the development of cerebrovascular diseases in stroke prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2003; 30: 44-8.
55. Riccioni G, D'orazio N, Speranza L, Franceschelli S. Marine carotenoids and CV risk markers. Mar Drugs 2011; 9: 1166-75.
56. Tsukui T, Konno K, Hosokawa M, Maeda H, Sashima T, Miyashita K. Fucoxanthin and fucoxanthinol enhance the amount of docosa-hexaenoic acid in liver of KKAy obese/diabetic mice. J Agric Food Chem 2007; 55: 5025-9.
57. Hadley CW, Clinton SK, Schwartz SJ. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. J Nutr 2003; 133: 727-32.
58. Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Kaplan GA, Salonen JT. Serum lycopene concentrations and carotid atherosclerosis: The Kuopio ischaemic heart disease risk factor study. Am J Clin Nutr 2003; 7: 133-8.
59. Adams CK, Campbell JK, Zaripheh S, Jeffery EH, Erdman JWJ. The tomato as a functional food. J Nutr 2005; 135: 1226-30.
60. Omoni AO, Aluko RE. The anti-carcinogenic and antiatherogenic effects of lycopene. Trends Food Sci Tech 2005; 16: 344-50.
61. Rissanen TH, Voutilainen S, Nyyssonen K, Salonen R, Salonen JT. Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. Arterioscler Thromb Vasc Biol 2000; 20: 2677-81.
62. Grobusch KK, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC. Serum carotenoids and ATS: The Rotterdam study. Atherosclerosis 2000; 148: 49-56.
63. Rissanen TH, Voutilainen S, Nyyssonen K, Salonen JT. Lycopene, atherosclerosis, and coronary heart disease. Exp Biol. Med 2002; 227: 900-7.
64. Sesso HD, Liu S, Gaziano JM, Buring JE. Dietary lycopene, tomatobased food products and cardiovascular disease in women. J Nutr 2003; 133: 2336-41.
65. Kaliora AC, Dedoussis GV, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 2006; 187: 1-17.
66. StahlW, Sies H. Lycopene: A biologically important carotenoid for humans? Arch Biochem Biophys 1996; 336: 1-9.
67. Riccioni G, Bucciarelli T, D'Orazio N, Palumbo N, DiIlio E, Corradi F, et al. Plasma Antioxidants and asymptomatic carotid atherosclerotic disease. Ann Nutr Metab 2008; 53: 86-90.
68. Agarwal S, Rao AV. Tomato lycopene and low density lipoprotein oxidation: A human dietary intervention study. Lipids 1998; 33: 981-4.
69. Martin KR, Wu D, Meydani M. The effect of carotenoids on the expression of cell surface adhesion molecules and binding of monocytes to human aortic endothelial cells. Atherosclerosis 2000; 150: 265-74.
70. Loppnow H, Westphal E, Buchorn R, Wessel A, Werdan K. IL-1 and related proteins in cardiovascular disease in adults and children. Shock 2001; 16: 3-9.
71. Chi H, Messas E, Levine RA, Graves DT, Amar S. IL-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: Pharmacotherapeutic implications. Circulation 2004; 110: 1678-85.
72. Libby P. Inflammation in ATS. Nature 2002; 420: 868-74.
73. Hu MY, Li YL, Jiang CH, Liu ZQ, Qu SL, Huang YM. Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits. Nutrition 2008; 24: 1030-8.
74. Kiran DK, Ahuja M, Pittaway JKB, Ball MJ. Effects of olive oil and tomato lycopene combination on serum lycopene, lipid profile, and lipid oxidation. Nutrition 2006; 22: 259-65.
75. Denniss SG, Haffner TD, Kroetsch JT, Davidson SR, Rush JWE, Hughson RL. Effect of short-term lycopene supplementation and postprandial dyslipidemia on plasma antioxidants and biomarker of endothelial health in young healthy individuals. Vasc Health Risk Manag 2008; 4: 213-22.
76. Rissanen TH, Voutilainen S, Nyyssonen K, Lakka TA, Sivenius J, Salonen R. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: The Kuopio ischaemic heart disease risk factor study. Br J Nutr 2001; 85: 749-54.
77. Gutierrez RJM, deCastro LMD. Lycopene: The need for better methods for characterization and determination. Trends Anal Chem 2007; 26: 163-70.
78. Agarwal A, Shen H, Agarwal S, Rao AV. Lycopene content of tomato products: Its stability, bioavailability and in vivo antioxidant properties. J Med Food 2001; 4: 9-15.
79. Gartner C, Stahl W, Sies H. Lycopene is more bioavailable from tomato paste than from fresh tomato. Am J Clin Nutr 1997; 66: 116-22.
80. Graziani G, Pernice R, Lanzuise S, Vitaglione P, Anese M, Fogliano V. Effect of peeling and heating on carotenoid content and antioxidant activity of tomato and tomato-virgin olive oil systems. Eur Food Res Technol 2003; 216: 116-21.
81. Sommerburg O, Keunen JEE, Bird AC, vanKiujk FJGM. Fruits and vegetables that are sources for lutein and zeaxanthin: The macular pigment in human eyes. Br J Ophthalmol 1998; 82: 907-10.
82. Gao S, Qin T, Liu Z, Caceres MA, Ronchi CF, Chen CYO, et al. Lutein and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens epithelial cells. Mol Vis 2011; 17: 3180-90.
83. Holden JM, Eldridge AL, Beecher GR. Carotenoid content of US foods: An update of the database. J Food Comp Anal 1998; 12: 169-96.
84. Arnal E, Miranda M, Barcia J, Bosch-Morell F, Romero FJ. Lutein and docosahexaenoic acid prevent cortex lipid peroxidation in streptozotocin-induced diabetic rat cerebral cortex. Neuroscience 2010; 166: 271-8.
85. Chiu CJ, Taylor A. Nutritional antioxidants, dietary carbohydrates, age-related maculopathy and cataract. Preventive nutrition: Comprehensive guide for health professionals. Hum Press 2010; 4: 501-44.
86. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E and risk of cataract in women: A prospective study. Arch Ophthalmol 2008; 126: 102-9.
87. Beebe DC, Holekamp NM, Shui YB. Oxidative damage and the prevention of age-related cataracts. Ophthalmic Res 2010; 44: 155-65.
88. Dilsiz N, Sahaboglu A, Yildiz M, Reichenbach A. Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefes Arch Clin Exp Ophthalmol 2006; 244: 627-33.
89. Peng CL, Lin ZF, Su YZ, Lin GZ, Dou HY, Zhao CX. The anti-oxidative function of lutein: Electron spin resonance studies and chemical detection. Funct Plant Biology 2006; 33: 839-46.
90. Krishaswamy R, Devaraj SN, Padma VV. Lutein protects HT-29 cells against Deoxynivalenol-induced oxidative stress and apoptosis: Prevention of NF-(B nuclear localization and down regulation of NF-(B and COX-2 expression. Free Radic Biol Med 2010; 49: 50-60.
91. Jin XH, Ohgami K, Shiratori K, Suzuki Y, Hirano T, Koyama Y, et al. Inhibitory effects of lutein on endo toxin-induced uveitis in Lewis rats. Inv Ophthalmol Vis Sci 2006; 47: 2562-8.
92. Ashino T, Yamanaka R, Yamamoto M, Shimokawa H, Sekikawa K, Iwakura Y, et al. Negative feedback regulation of LPS-induced inducible NOS gene expression by HMOX-1 induction in macrophages. Mol Immunol 2008; 45: 2106-15.
93. Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Manson JE, Willet WC. Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr 2003; 77: 1390-9.
94. Kim JE, Leite JO, DeOgburn R, Smyth JA, Clark RM, Fernandez ML. A lutein-enriched diet prevents cholesterol accumulation and decreases ox-LDL and inflammatory cytokines in the aorta of guinea pigs. J Nutr 2011; 141: 1458-63.
95. Zou Z, Xu X, Huang Y, Xiao X, Ma L, Sun T, et al. High serum level of lutein may be protective against early ATS: The Beijing atherosclerosis study. Atherosclerosis 2011; 219: 789-93.
96. Kritchevsky SB, Tell GS, Shimakawa T. Provitamin A carotenoid intake and carotid artery plaques: The atherosclerosis risk in communities study. Am J Clin Nutr 1998; 68: 726-33.
97. McQuillan BM, Hung J, Beilby JP. Antioxidant vitamins and the risk of carotid atherosclerosis. The perth carotid ultrasound disease assessment study (CUDAS). J Am Coll Cardiol 2001; 38: 1788-94.
98. Dwyer JH, Navab M, Dwyer KM. Oxygenated carotenoid lutein and progression of early ATS: The Los Angeles atherosclerosis study. Circulation 2001; 103: 2922-7.
99. Dwyer JH, Paul-Labrador MJ, Fan J. Progression of carotid intima-media thickness and plasma antioxidants: The Los Angeles atherosclerosis study. Arterioscler Thromb Vasc Biol 2004; 24: 313-19.
100. Hozawa A, Jacobs JDR, Steffes MW, Gross MD, Steffen LM, Lee DH. Circulating carotenoid concentrations and incident hypertension: The coronary artery risk development in young adults (CARDIA) study. J Hypertens 2009; 27: 237-42.
101. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia reperfusion-injury, a clinical view on complex pathophysiological process. Int J Card 2005; 100: 179-90.
102. Saeed SA, Waqar MA, Zubairi AJ, Bhurgri H, Khan A, Gowani SA. Myocardial ischaemia and reperfusion injury: Reactive oxygen species and the role of neutrophil. J Coll Physicians Surg Pak 2005; 15: 507-14.
103. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181-90.
104. Voutilainen S, Nurmi T, Mursu J, Rissanen TH. Carotenoids and cardiovascular health. Am J Clin Nutr 2006; 83: 1265-71.
105. Adluri RS, Thirunavukkarasu M, Zhan L, Maulik N, Svennevig K, Bagchi M, et al. Cardio-protective efficacy of a novel antioxidant mix vitaepro against ex vivo myocardial ischemia-reperfusion injury. Cell Biochem Biophys 2011; 30: 9300-7.
106. Pfander H. Carotenoids: An over-view. Methods Enzymol 1992; 213: 3-13.
107. Mares-Perlman JA., Millen AE, Ficek TL, Hankinson SE. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. J of Nutrition 2002; 132: 518-24S.
108. Giblin FJ. Glutathione: A vital lens antioxidant. J Ocul Pharmacol Ther 2000; 16: 121-35.
109. Tanumihardjo SA, Yang Z. Carotenoids: Epidemiology of health effects. In: Caballero B, Allen L, Prentice A, eds. Encyclopedia of human nutrition. 2nd ed. Oxford: Elsevier Ltd; 2005, pp. 339-345.
110. Johnson EJ. The role of carotenoids in human health. Nutr Clin Care 2002; 5: 56-65.
111. Pattison DJ, Symmons DPM, Lunt M, Welch A, Bingham SA, Day NE, et al. Dietary b-cryptoxanthin and inflammatory polyarthritis: Results from a population-based prospective study. Am J Clin Nutr 2005; 82: 451-5.
112. Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell L. Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol 2003; 157: 345-54.
113. Kritchevsky SB, Bush AJ, Pahor M, Gross MD. Serum carotenoids and markers of inflammation in non-smokers. Am J Epidemiol 2000; 152: 1065-71.
114. Suzuki K, Ito Y, Ochiai J. Relationship between obesity and serum markers of oxidative stress and inflammation in Japanese. Asian Pac J Cancer Prev 2003; 4: 259-66.
115. Ross AC, Zolfaghari R, Weisz J. Vitamin A: Recent advances in the biotransformation, transport, and metabolism of retinoids. Curr Opin Gastroenterol 2001; 17: 184-92.
116. Jialal I, Norkus EP, Cristol L, Grundy SM. Beta-Carotene inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1991; 1086: 134-8.
117. Robbins M, Topol EJ. Inflammation in acute coronary syndromes. Cleve Clin J Med 2002; 69: 130-42.
118. DiTomo P, Canali R, Ciavardelli D, DiSilvestre S, DeMarco A, Giardinelli A, et al. B-carotene and lycopene affect endothelial response to TNF-A reducing nitro-oxidative stress and interaction with monocytes. Mol Nutr Food Res 2011; 55: 1-11.
119. Aizawa T, Wei H, Miano JM, Abe J. Role of PDE-3 in NO/cGMP-mediated anti-inflammatory effects in vascular smooth muscle cells. Circ Res 2003; 93: 406-13.
120. Shaish A, Harari A, Hananshvili L, Cohen H, Bitzur R, Luvish T, et al. 9-cis beta-Carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-c in fibrate treated patients. Atherosclerosis 2006; 189: 215-21.
121. Harari A, Harats D, Marko D, Cohen H, Barshack I, Kamari Y, et al. A 9-cis b-Carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL-R knockout mice. J Nutr Dis 2008; 138: 1923-30.
122. Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther 2006; 10: 93-100.
123. Riccioni G, D'Orazio N, Palumbo N, Bucciarelli V, DiIlio E, Bazzano LA, et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: The asymptomatic carotid atherosclerotic disease in Manfredonia study. Eur J Card Prev Rehabil 2009; 16: 351-7.
124. Lobo GP, Amengual J, Li HNM, Golczak M, Bonet ML, Palczewski K, et al. Beta-Carotene decreases PPR-Alpha activity and reduces lipid storage capacity of adipocytes in a beta-carotene oxygenase 1-dependent manner. J Biol Chem 2010; 285: 27891-99.
125. Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA. Retinoic acid blocks adipogenesis by inhibiting C/EBPbetamediated transcription. Mol Cell Biol 1997; 17: 1552-61.
126. Mercader J, Granados N, Bonet ML, Palou A. All-trans retinoic acid decreases murine adipose retinol binding protein 4 production. Cell Physiol Biochem 2010; 22: 363-72.
127. Ramakrishna V, Jailkhani R. Oxidative stress in non insulin dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 2008; 45: 41-6.
128. Musch DC. Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration. JAMA Ophthalmol 2014; 132: 139-41.